ABSTRACT
Background: To tackle the 2019 coronavirus infection (COVID-19) disease pandemic, effective antiviral therapy is critical. We assessed the efficacy of sofosbuvir and daclatasvir for treating patients with COVID-19. Methods: This was a randomized controlled trial in adults with moderate-to-severe COVID-19 disease admitted to Razi Teaching Hospital in Ahvaz, Khuzestan Province, Iran. Patients were randomly assigned to the sofosbuvir and daclatasvir group (n=35, intervention group) and control group (n=35, standard care). The primary endpoint of this study was the length of hospital stay, clinical improvement, mechanical ventilation, mortality, and side effect. Results: We found that the combination of Daclatasvir and Sofosbuvir (DCV+SOF) did not make a statistically significant difference in terms of mortality. There was no significant difference in the duration of hospitalization between the two groups. The two groups did not differ significantly in terms of the frequency of side effects. There were 2 cases of intubation and death in both groups. Conclusion: The medications used in this study, i.e, the combination of daclatasvir and sofosbuvir, failed to show a significant effect in patients, and despite promising laboratory studies, there were no improvements observed in vital signs and the indicators studied, including clinical signs. Hospitalization days, ventilator requirements and mortality did not make a significant difference. To confirm the results of this study, conducting researches with a larger sample size are needed. © 2022 Seventh Sense Research Group®
ABSTRACT
This study investigated the relationship between cardiopulmonary radiological manifestations of patients undergoing ICU. Numerous complications have been reported following Covid-19 disease, sustained fibrotic changes following clinical improvement, bacterial and fungal lung infections, ARDS, pneumomediastinum and pneumothorax, myocardial and pericardial involvement, and pulmonary artery embolism are all important complications. Reportedly looking for coronavirus infection. Various imaging techniques, especially chest CT scan, not only play an important role in the initial diagnosis of the disease, but are also widely used to follow the treatment process and diagnose possible secondary complications. Various diagnostic methods such as serological, molecular, and radiological can assist health centers in diagnosing Covid-19;Today, molecular methods and radiography are used as the main methods of diagnosing Covid-19 disease. Radiology technique is known as one of the most suitable methods for diagnosing viral infections due to its high speed and accuracy and less false negative response in this field.Based on the results of this study, it is suggested that for the correct and timely diagnosis of this disease, especially in asymptomatic patients, several diagnostic methods should be used and different samples of the patient should be evaluated.It is also recommended that due to the lack of effective treatment and vaccines, the best way to deal with this disease is to avoid infection and prevent its spread through protective measures and personal hygiene.
ABSTRACT
Background: Hypertension is the main factor to predict the severity and mortality of COVID-19. The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is challenging. This study aimed to investigate the effect of ACEIs and ARBs on clinical outcomes in COVID-19 patients with hypertension. Materials and Methods: This cross-sectional study was carried out on 498 patients who were referred to Razi hospital following COVID-19 development and also had hypertension. Patients were divided into two groups receiving drugs in the ACEIs and ARB's groups and those not receiving these drugs. The primary outcome was death up to one month after the onset of symptoms. Results: Cardiovascular disease in patients taking ACEIs/ARBs was higher (p<0.001). One hundred eleven deaths (22.3%) were seen in the studied patients in whom 66 deaths (59.5%) belonged to the group not taking ACEIs and ARBs (p>0.05). Seventy-nine patients (15.86%) were admitted to ICU in which 62.03% of these patients died while the non-ICU mortality rate was 14.8% (Odds Ratio = 9.40;95% CI: 5.54 to 15.95, p <0.001). A subgroup analysis found that among patients with diabetes who had hypertension, the incidence of death was 43.55% in the group taking ARBs/ACEi lower than in another group significant (p = 0.021). Conclusion: The mortality rate in the patients taking ACEIs/ARBs is not different from other groups. It was found that among COVID-19 patients with diabetes who had hypertension, the incidence of death in the patients taking ARBs/ACEi was lower than in another group. © 2021 Universitas Gadjah Mada - Faculty of Pharmacy. All rights reserved.
ABSTRACT
Introduction: Since the Covid-19 pandemic, research has focused on identifying people at risk and preventing its spread. The aim of this study was to investigate the relationship between blood groups (ABO) and the risk of COVID-19 infection in Shahroud.